Figure 2.

Survival curves of 3-year OS, OS, and PFS of ESCC patients according to HPV16, p75NTR, and PI3K expression.

Notes: Kaplan–Meier estimates of survival among esophageal squamous cell carcinoma (ESCC) patients, according to the tumor human papillomavirus 16 (HPV16) status or p75 neurotrophin receptor (p75NTR)-expression status or phosphatidylinositol 3-kinase (PI3K)-expression status; For the 5-year overall survival (OS) rate (A) and progression-free survival (PFS) rate (D), HPV16 positive is significantly associated with poor prognosis (P=0.021, P=0.04, respectively); For the 5-year OS rate (B) and PFS rate (E), there is no relationship between p75NTR expression and prognosis (P=0.312, P=0.368, respectively); For the 5-year OS rate (C) and PFS rate (F), PI3K positive is significantly associated with poor prognosis (P=0.011, P=0.006, respectively); Consistently, for the 3-year OS rate, HPV16 and PI3K positive (G, H, respectively) are significantly correlated with poor prognosis (P=0.005, P=0.025, respectively) while there is still no association between p75NTR and prognosis (I, P=0.408).